Results 171 to 180 of about 2,458 (200)
Some of the next articles are maybe not open access.
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy
Expert Review of Anticancer Therapy, 2021Introduction: The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically with the introduction of novel targeted therapies. Phosphoinotiside-3 kinase (PI3K) is a B-cell receptor-associated kinase that is essential for growth, survival and migration of neoplastic B cells and is implicated in disease progression and drug ...
Liana, Nikolaenko +2 more
openaire +2 more sources
Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma
International Journal of Hematology, 2020Duvelisib is a novel dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ. This single-arm, multicenter phase I study investigated its safety, pharmacokinetics, and preliminary efficacy in Japanese patients with relapsed or refractory lymphoma. Duvelisib was administered orally twice daily at 25 mg in 28-day cycles.
Koji Izutsu +5 more
openaire +2 more sources
Duvelisib: First Global Approval
Drugs, 2018Duvelisib (Copiktra™) is a small-molecule inhibitor of phosphatidylinositol-3 kinase that has been developed as an oral treatment for various cancer indications. In September 2018, duvelisib received its first global approval in the USA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/small lymphocytic
openaire +2 more sources
Duvelisib: A New Phosphoinositide-3-Kinase Inhibitor in Chronic Lymphocytic Leukemia
Future Oncology, 2019P110-γ and -δ act in lymphocytes chemotaxis, presenting distinct, nonredundant roles in B- and T-cell migration and adhesion to stromal cells. Moreover, phosphoinositide-3-kinase-γ inhibition contributes to regulate macrophage polarization inhibiting cancer growth.
Anna M Frustaci +5 more
openaire +3 more sources
Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy
Blood, 2023Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of patients with advanced non-Hodgkin lymphoma (NHL). However, treatment toxicity, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS), can be significant.
Michael Slade +10 more
openaire +1 more source
Duvelisib: A comprehensive profile
Duvelisib (DUV) is chemically named as (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one. It is a novel drug with a small molecular weight and characterized by dual phosphoinositide-3-kinase (PI3K)- and PI3K-inhibitory activity.Haya I, Aljohar +4 more
openaire +2 more sources
Duvelisib, a PI3K-δ,γ inhibitor, in subjects with mild asthma
5.1 Airway Pharmacology and Treatment, 2015Background: Duvelisib (IPI-145), an oral phosphoinositide-3-kinase (PI3K)-δ,γ inhibitor, has shown activity in preclinical models of inflammation, including lung inflammation. Based on these findings, Study IPI-145-03 (ClinicalTrials.gov NCT01653756) was initiated in patients (pts) with asthma.
Tess Schmalbach +8 more
openaire +1 more source
Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).
Journal of Clinical Oncology, 201812048Background: Duvelisib (IPI-145) (DUV) is an oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-δ and PI3K-γ being developed to treat B-cell malignancies.
David T. Weaver +19 more
openaire +1 more source
Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
BloodIntroduction: Both duvelisib, a phosphoinositive-3-kinase (PI3K)-γδ inhibitor, and ruxolitinib, a Janus kinase (JAK)-1/2 inhibitor, are effective agents for peripheral and cutaneous T cell lymphomas (PTCL and CTCL) that appear to target active, yet parallel, pathways in these diseases.
Alison Moskowitz +35 more
openaire +1 more source